Dozens of people claiming to have sustained eye damage from using GLP-1 medications are suing Eli Lilly and Novo Nordisk, the makers of the blockbuster drugs.1Semaglutide and tirzepatide are now among the most widely used drugs to treat type 2 diabetes and promote weight loss.Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist marketed by Novo Nordisk under the brand names Ozempic, Wegovy, and Rybelsus. Tirzepatide, which acts on GLP-1 and glucose dependent insulinotropic polypeptide (GIP) receptors, is produced by Eli Lilly and available under the brand names Mounjaro and Zepbound.The condition at the centre of the lawsuits is non-arteritic anterior ischaemic optic neuropathy (NAION). It is sometimes described as a “stroke” of the optic nerve and is the most common acute optic neuropathy in people over 50.2Kevin Gendreau, an obesity medicine physician at the Weight & Wellness Center at Signature Healthcare in Brockton, Massachusetts, said of NAION: “Blood flow to...

A lack of equity, diversity, inclusion, and accessibility (EDIA) considerations is a well described challenge that threatens the scientific and ethical integrity of healthcare research.1 Underrepresentation is costly, unjust, and harms patients.1 Unintentional exclusion of patients who may most benefit from trial evidence is a central focus of many efforts to improve EDIA considerations in research, with the exclusion of black participants from cancer trials being an important example.1 Intentional exclusion of pregnant23 or cognitively impaired45 participants from trials that may most benefit these populations is an emerging area of concern. Further, a lack of understanding of structural discrimination relevant to the trial discipline can lead to erroneous conclusions. An important example is attributing findings from observational studies showing worse outcomes from covid-19 infection in black populations6 to biological mechanisms7 without considering how systemic overestimation of blood oxygen by pulse oximetry used on skin of colour8 influences access to treatments...

F. Gordo Vidal
Med Intensiva. 2023;47:191-2

Texto completo - PDF

Francisco Álvarez-Lerma, Mercedes Catalán-González, Joaquín Álvarez, Miguel Sánchez-García, Mercedes Palomar-Martínez, Inmaculada Fernández-Moreno, José Garnacho-Montero, Fernando Barcenilla-Gaite, Rosa García, Jesús Aranaz-Andrés, Francisco J. Lozano-García, Paula Ramírez-Galleymore, Montserrat Martínez-Alonso
Med Intensiva. 2023;47:193-202

Resumen - Texto completo - PDF

P. Perelló, J. Gómez, J. Mariné, M.T. Cabas, A. Arasa, Z. Ramos, D. Moya, I. Reynals, M. Bodí, M. Magret
Med Intensiva. 2023;47:203-11

Resumen - Texto completo - PDF

E.P. Gomes, M.M. Reboredo, G.B. Costa, F.S. Barros, E.V. Carvalho, B.V. Pinheiro
Med Intensiva. 2023;47:212-20

Resumen - Texto completo - PDF

L. Zapata, C. Guía, R. Gómez, T. García-Paredes, L. Colinas, E. Portugal-Rodriguez, I. Rodado, I. Leache, A. Fernández-Ferreira, I.A. Hermosilla-Semikina, F. Roche-Campo
Med Intensiva. 2023;47:221-31

Resumen - Texto completo - PDF

I. Astola Hidalgo, A. Fernández Rodríguez, E. Martínez Revuelta, M. Martínez Revuelta, A.M. Ojea, P. Herrero Puente, D. Escudero Augusto
Med Intensiva. 2023;47:232-4

Texto completo - PDF

F.J. Casadiego Monachello, M.C. de la Torre Terron, J.A. Mendez Barraza, S. Casals Vila
Med Intensiva. 2023;47:235-7

Texto completo - PDF

M.V.F. Garcia, R. Souza, P. Caruso
Med Intensiva. 2023;47:237-9

Texto completo - PDF

J.M. Pérez Villares, L. Alarcón Martínez, P. Fernández Florido
Med Intensiva. 2023;47:239-41

Texto completo - PDF

A. González-Castro, E. Cuenca Fito, C. González
Med Intensiva. 2023;47:242

Texto completo - PDF

M. Cuervas-Mons Tejedor, J.D. López Castilla, E. Sánchez Valderrábanos
Med Intensiva. 2023;47:243

Texto completo - PDF

L.I. Perez-Sanchez, N. Mamolar Herrera, J.J. Velasco Gómez
Med Intensiva. 2023;47:244-5

Texto completo - PDF

M.C. Martínez-Ávila, C.I. Herrera-Arrieta, Z.M. Mondol-Almeida
Med Intensiva. 2023;47:246-7

Texto completo - PDF

I. Keituqwa Yáñez, J. Navarro Martínez, M. García Valiente
Med Intensiva. 2023;47:248-9

Texto completo - PDF

Á. Orera Pérez, A. Riaño Ondiviela, E. Sanz Granado
Med Intensiva. 2023;47:250-1

Texto completo - PDF

C. Chamorro-Jambrina, D. Palacios-Castañeda, E.E. Ebrat-Mancilla
Med Intensiva. 2023;47:252-3

Texto completo - PDF

J. Trenado-Alvarez
Med Intensiva. 2023;47:129-30

Texto completo - PDF

L. Cattin, F. Ferrari, S. Mongodi, E. Pariani, G. Bettini, F. Daverio, K. Donadello, E. Polati, F. Mojoli, V. Danzi, S. De Rosa
Med Intensiva. 2023;47:131-9

Resumen - Texto completo - PDF